YSA + TAT (dual-peptide nanoparticle)
Sequence: YSA: YSAYPDSVPMMS; TAT: AYGRKKRRQRRR
| Experiment Id | EXP002102 |
|---|---|
| Paper | Engineering a nano-drug delivery system to regulate m6A modification and enhance immunotherapy in ga |
| Peptide | YSA + TAT (dual-peptide nanoparticle) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | surface-modified on PLGA nanoparticles |
| Rna Concentration | 5–10 mg/kg STM equivalent |
| Mixing Ratio | |
| Formulation Format | biomimetic nanoparticle with CPP and targeting peptide |
| Formulation Components | PLGA + STM2457 + TAT + cancer cell membrane + YSA |
| Size Nm | 126.00 |
| Zeta Mv | -2.50 |
| Model Scope | in_vivo |
| Model Type | in vitro and in vivo |
| Cell Lines Or Primary Cells | SGC-7901; AGS; HGC-27; MFC; B16-F10-luc |
| Animal Model | Mouse xenograft and metastasis models |
| Administration Route | intravenous (tail vein) |
| Output Type | tumor growth suppression; immune activation |
| Output Value | Significant tumor regression; reduced metastasis; improved survival |
| Output Units | |
| Output Notes | YSA enables EphA2 targeting; TAT enables cell entry; strong in vivo efficacy alone and with anti-PD1 |
| Toxicity Notes | No significant systemic toxicity observed |
| Curation Notes |